Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus VEKLURY.
INCIVEK vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category C
Category C
Antiviral
Antiviral